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MaThis paper tackles several statistical controversies that are commonly faced when reporting a major clinical trial. Topics
covered include: multiplicity of data, interpreting secondary endpoints and composite endpoints, the value of covariate
adjustment, the traumas of subgroup analysis, assessing individual beneﬁts and risks, alternatives to analysis by intention
to treat, interpreting surprise ﬁndings (good and bad), and the overall quality of clinical trial reports. All is put in
the context of topical cardiology trial examples and is geared to help trialists steer a wise course in their statistical
reporting, thereby giving readers a balanced account of trial ﬁndings. (J Am Coll Cardiol 2015;66:2648–62)
© 2015 by the American College of Cardiology Foundation.L ast week’s review paper covered the funda-mentals of statistical analysis and reportingof randomized clinical trials (RCTs). We now
extend those ideas to discuss several controversial
statistical issues that are commonly faced in the pre-
sentation and interpretation of trial ﬁndings.
We explore the problems faced by investigators
due to the multiplicity of data available from any
RCT, especially regarding multiple endpoints and
subgroup analyses. Interpreting composite endpoints
is a particular challenge. There is an inconsistency
regarding the use of covariate-adjusted analyses.
There is a need for more trials to assess how their
overall ﬁndings can be translated into assessment of
an individual patient’s absolute beneﬁts and absolute
risks. The merit of analysis by intention to treat (ITT)
is considered alongside other options, such as on-
treatment analysis. One rarely discussed topic is
how to interpret surprisingly large treatment effects
(both good and bad) in new trials, which are often
quite small in scale.m the *Department of Medical Statistics, London School of Hygiene & T
stitute of Cardiovascular and Medical Sciences, University of Glasgow, Gl
t they have no relationships relevant to the contents of this paper to dis
nuscript received September 8, 2015; revised manuscript received OctobeAll of these controversies are summarized in the
Central Illustration and are illustrated by topical ex-
amples from cardiology trials. The overall aim in
clarifying these issues is to enhance the quality of
clinical trial reports in medical journals. The same
principles apply to conference presentations and
sponsor press releases, which are even more prone to
distortive reporting.
MULTIPLICITY OF DATA
The key challenge in any report of a major RCT is how
to provide a balanced account of the trial’s ﬁndings,
given the large number of variables collected at
baseline and during follow-up, commonly called a
“multiplicity of data” (1). So, out of the potential
chaos of the innumerable tables and ﬁgures that
could be produced for purposes of treatment com-
parison, how do we validly select what to include in
the ﬁnite conﬁnes of a trial publication in a major
journal? Especially, how do we ensure that such aropical Medicine, London, United Kingdom; and the
asgow, United Kingdom. The authors have reported
close.
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AB BR E V I A T I O N S
AND ACRONYM S
CABG = coronary artery bypass
graft
CI = conﬁdence interval
DES = drug-eluting stent
ITT = intention to treat
MACCE = major adverse
cardiac or cerebrovascular
events
MI = myocardial infarction
PCI = percutaneous coronary
intervention
RCT = randomized clinical trial
SAP = statistical analysis plan
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2649condensed trial report is fair in what it includes; that
is, how do we resist the temptation to “play up the
positive” by devoting more space in the results and
conclusions sections to those ﬁndings that put the
new treatment in a good light?
A ﬁrst step to overcome this is to have a pre-
deﬁned statistical analysis plan (SAP) that is fully
signed off before database locking and study
unblinding. This SAP is prepared by trial statisticians
and approved by the trial executive, all of whom
must be blind to any interim results by treatment
group. A good SAP will not only document exactly
which analyses are to be done, but will also eluci-
date relevant priorities in their interpretation,
especially regarding the primary hypothesis, sec-
ondary hypotheses, any pre-deﬁned safety concerns,
and a potential plethora of exploratory analyses
(e.g., subgroup analyses), which are more hypothesis-
generating in spirit.
A particular focus is on the pre-deﬁned primary
endpoint, with clear deﬁnition of the endpoint itself,
the time of follow-up included (either a ﬁxed period
[e.g., 90 days], or a ﬁxed calendar date for follow-up
of all patients), and the precise statistical method for
determining its point estimate, conﬁdence interval
(CI), and p value. For time-to-event outcomes this is
commonly a hazard ratio (HR) (and 95% CI) with log-
rank p value, but sometimes a covariate-adjusted
analysis is primary (see later discussion on this).
It is good practice to have a pre-deﬁned and limited
set of secondary endpoints for treatment efﬁcacy.
Their results are shown alongside those of the pri-
mary endpoint; for example, as in Table 1 for the
PEGASUS-TIMI 54 (Prevention of Cardiovascular
Events in Patients With Prior Heart Attack Using
Ticagrelor Compared to Placebo on a Background of
Aspirin—Thrombolysis In Myocardial Infarction 54)
trial (2), comparing 2 doses of ticagrelor with aspirin
in patients with prior myocardial infarction (MI).
In this instance, the interpretation appears to be
straightforward because the primary endpoint ach-
ieved statistical signiﬁcance for each ticagrelor dose
versus placebo and all secondary efﬁcacy endpoints
showed trends in the same direction, except for no
difference in all-cause death for the higher ticagrelor
dose. However, excesses of major bleeding and dys-
pnea on ticagrelor mean that such efﬁcacy is offset by
safety concerns.
But when the primary endpoint ﬁndings are
inconclusive, claims of efﬁcacy for any secondary
endpoints are more of a challenge. For instance, the
PROactive (Prospective pioglitazone clinical trial in
macrovascular events) (3) trial of pioglitazone versus
placebo in 5,238 diabetic patients had a primarycomposite endpoint of death, MI, stroke,
acute coronary syndrome, endovascular sur-
gery, or leg amputation. Over a mean 3 years
of follow-up, the HR was 0.90 (95% CI: 0.80
to 1.02; p ¼ 0.095). The main secondary
endpoint, the composite of death, MI, and
stroke, had an HR of 0.84 (95% CI: 0.72 to
0.98; p ¼ 0.027). The publication’s conclu-
sions highlighted the latter and downplayed
the lack of statistical signiﬁcance for the pri-
mary endpoint, whereas a more cautious
interpretation is usually warranted.
In contrast, the publication of the MATRIX
(Minimizing Adverse Hemorrhagic Events by
Transradial Access Site and Systemic Imple-
mentation of Angiox) trial (4), comparing
bivalirudin or unfractionated heparin in acute coro-
nary syndromes, had conclusions conﬁned to the
coprimary endpoints of major adverse cardiovascular
(CV) events (death, MI, or stroke) and net adverse
clinical events (death, MI, stroke, or major bleed),
both of which “were not signiﬁcantly lower with
bivalirudin than with unfractionated heparin.”
Whereas the focus on primary endpoints is appro-
priate, there is a danger that it can hide important
differences among secondary (component) end-
points. Although cautious interpretation is essential
across a multiplicity of secondary endpoints, the
conclusions would have beneﬁted from mentioning
that bivalirudin had more stent thromboses
(p ¼ 0.048), fewer major bleeds (p < 0.001), and fewer
deaths (p ¼ 0.04). Such intriguing secondary ﬁndings
need clariﬁcation from other related trials.
When a secondary endpoint reveals the potential
harm of a treatment, controversy is likely to ensue.
For instance, in the SAVOR-TIMI 53 (Saxagliptin
Assessment of Vascular Outcomes Recorded in
Patients with Diabetes Mellitus—Thrombolysis In
Myocardial Infarction 53) trial (5) of saxagliptin
versus placebo in diabetic patients, the composite
primary endpoint (CV death, MI, and stroke) showed
no treatment difference, but 1 of several secondary
endpoints, heart failure hospitalization, revealed an
excess on saxagliptin (HR: 1.27; 95% CI: 1.07 to 1.51;
p ¼ 0.007). The risk of a type I error (false positive)
runs high when looking at multiple endpoints (1 pri-
mary and 10 secondary in this instance), so the play of
chance cannot be ruled out. The 2 subsequent
EXAMINE (Examination of Cardiovascular Outcomes
with Alogliptin versus Standard of Care) (6) and
TECOS (Trial Evaluating Cardiovascular Outcomes
with Sitagliptin) (7) trials of drugs in the same class,
alogliptin and sitagliptin, respectively, revealed no
excess of heart failure, and there is no plausible
TABLE 1 Efﬁcacy En
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Stroke, MI, death,
bleeding...
Diabetic
Hypertension
Age
Angina
Race
Weight
Sex
Influencing variables
Age, sex, diabetes,
previous MI...
Outcome variables
Multiplicity of data
How to make sense 
of all the options?
Covariate adjustment
Should key results
be adjusted for 
baseline covariates?
Subgroup analysis
Which subgroups 
should be explored?
Individual benefits 
and risks
How to link
trial findings to 
individualised
patient care?
Intention to treat 
(ITT) analysis
How to deal
with non-adherence 
during follow-up?
• Adjust for variables 
affecting prognosis
• Pre-define variables 
and model chosen
• Consider covariate 
adjustment as 
primary analysis
• Focus on pre-defined 
subgroups
• Analyse using 
interaction tests not 
subgroup P-values
• Interpret all 
subgroup findings 
with caution
• Balance absolute 
benefits against 
absolute harms
• Consider individual 
risk profile in 
determining their 
treatment benefit
• Utilize multivariable 
risk models rather 
than univariable 
subgroups
• Prioritize analysis
by ITT
• If patient withdraws 
from treatment 
continue follow-up 
if possible
• Avoid poor 
compliance and
loss to follow-up
• For non-inferiority 
trials present both 
ITT and as treated 
analyses
Interpreting
surprising results
What to do
when unexpected 
findings arise?
• Seek evidence to 
confirm (or not) as 
soon as possible
• Be skeptical of
large effects 
• Anticipate regression 
to the truth
• Avoid alarmist 
reactions to 
unexpected
safety signals
• Prepare a pre-
defined Statistical 
Analysis Plan
• Give priority to 
primary endpoint
• Present a balanced 
account of safety
and efficacy
• Interpret composite 
endpoints carefully
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ITT ¼ intention to treat; MI ¼ myocardial infarction.
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2650biological explanation as to why the drugs might
differ in this respect. Furthermore, a statistical test of
heterogeneity comparing the 3 trials’ HRs for heart
failure is not statistically signiﬁcant (interaction p ¼dpoints for the PEGASUS-TIMI 54 Trial
Ticagrelor, 90 mg
(n ¼ 7,050)
Ticagrelor, 60 mg
(n ¼ 7,045)
Placebo
(n ¼ 7,067
I, or stroke* 493 (7.85) 487 (7.77) 578 (9.04
eart disease, MI, 438 (6.99) 445 (7.09) 535 (8.33
r MI 424 (6.79) 422 (6.77) 497 (7.81
eart disease or MI 350 (5.59) 360 (5.75) 429 (6.68
182 (2.94) 174 (2.86) 210 (3.39
eart disease 97 (1.53) 106 (1.72) 132 (2.08
275 (4.40) 285 (4.53) 338 (5.25
100 (1.61) 91 (1.47) 122 (1.94
88 (1.41) 78 (1.28) 103 (1.65
326 (5.15) 289 (4.69) 326 (5.16
herwise indicated. Number of events, 3-year Kaplan-Meier estimates, and hazard ratios for
ttack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis In M
; HR ¼ hazard ratio; MI ¼ myocardial infarction.0.16), and the combined HR is 1.13 (p ¼ 0.04) and 1.12
(p ¼ 0.18) for ﬁxed and random-effect meta-analyses,
respectively (Figure 1). This analysis partly hinges on
the concept that similar effects should be expected)
Ticagrelor, 90 mg vs. Placebo Ticagrelor, 60 mg vs. Placebo
HR (95% CI) p Value HR (95% CI) p Value
) 0.85 (0.75–0.96) 0.008 0.84 (0.74–0.95) 0.004
) 0.82 (0.72–0.93) 0.002 0.83 (0.73–0.94) 0.003
) 0.85 (0.75–0.97) 0.01 0.85 (0.74–0.96) 0.01
) 0.81 (0.71–0.94) 0.004 0.84 (0.73–0.96) 0.01
) 0.87 (0.71–1.06) 0.15 0.83 (0.68–1.01) 0.07
) 0.73 (0.56–0.95) 0.02 0.80 (0.62–1.04) 0.09
) 0.81 (0.69–0.95) 0.01 0.84 (0.72–0.98) 0.03
) 0.82 (0.63–1.07) 0.14 0.75 (0.57–0.98) 0.03
) 0.85 (0.64–1.14) 0.28 0.76 (0.56–1.02) 0.06
) 1.00 (0.86–1.16) 0.99 0.89 (0.76–1.04) 0.14
efﬁcacy endpoints in the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in
yocardial Infarction 54) trial. Data from Bonaca et al. (2). *Primary endpoint.
FIGURE 1 Assessing the Evidence for Excess Heart Failure Across 3 Related
Placebo-Controlled Trials in Type 2 Diabetes
Trial Hazard Ratio(95% CI)
0.8 1.0 1.2 1.4
Hazard Ratio for Heart Failure Hospitalization
SAVOR-TIMI 53
EXAMINE
TECOS
Overall (fixed effect)
Overall (random effect)
heterogeneity P=0.16
1.27 (1.07, 1.50)
1.07 (0.79, 1.45)
1.00 (0.83, 1.20)
1.13 (1.01, 1.27)
1.12 (0.95, 1.32)
Forest plot showing study-speciﬁc and pooled (ﬁxed effect and random effects) hazard
ratios for heart failure from the SAVOR-TIMI 53, EXAMINE, and TECOS trials. CI ¼ conﬁ-
dence interval; EXAMINE ¼ Examination of Cardiovascular Outcomes with Alogliptin versus
Standard of Care; SAVOR-TIMI 53 ¼ Saxagliptin Assessment of Vascular Outcomes
Recorded in Patients with Diabetes Mellitus—Thrombolysis In Myocardial Infarction 53;
TECOS ¼ Trial Evaluating Cardiovascular Outcomes with Sitagliptin.
TABLE 2 A Summary of Key 1- and 5-Year Findings From the SYNTAX Trial
Endpoint
1-Year Event Rates 5-Year Event Rates
CABG
(n ¼ 897)
DES
(n ¼ 903)
p
Value
CABG
(n ¼ 897)
DES
(n ¼ 903)
p
Value
MACCE composite* 12.1 17.8 0.002 26.9 37.3 <0.0001
Death 3.5 4.4 0.37 11.4 13.9 0.10
MI 3.3 4.8 0.11 3.8 9.7 <0.0001
Stroke 2.2 0.6 0.003 2.4 3.7 0.09
Death/MI/stroke 7.6 7.5 0.98 16.7 20.8 0.03
Repeat revascularization 5.9 13.7 <0.001 13.7 25.9 <0.0001
PCI 4.7 11.4 <0.001
CABG 1.3 2.8 0.03
Values are % of patients experiencing the composite primary endpoint (MACCE) and its components at 1 and 5
years in the SYNTAX trial. *MACCE is the pre-deﬁned primary composite of death, MI, stroke, and repeat
revascularization.
CABG ¼ coronary artery bypass graft; DES ¼ drug-eluting stents; MACCE ¼ major adverse cardiac or cere-
brovascular events; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; SYNTAX ¼ Synergy
between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery.
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2651for drugs in the same class. This is often the case, but
there are exceptions: for example, torcetrapib versus
other cholesteryl ester transfer protein inhibitors, and
ximelagatran versus other direct thrombin inhibitors
regarding liver abnormalities. Thus, although one
cannot rule out the possibility of a real problem here
unique to saxagliptin, the evidence of harm lacks
conviction and should be interpreted with caution.
Regulatory authorities and trial publications in
medical journals have somewhat different perspec-
tives when it comes to interpreting secondary end-
points. If the primary endpoint is neutral, the efﬁcacy
claims for secondary endpoints may be cautiously
expressed in the published medical data (usually
with less emphasis than authors might wish),
although it is highly unlikely that regulators will
approve a drug on this basis. Regulators face a
dilemma when secondary endpoint suggestions of
potential harm arise, as in the SAVOR-TIMI 53 trial
(5). There is an asymmetry here in that the corre-
sponding extent of evidence in the direction of
treatment beneﬁt would receive scant attention.
Although there is an obvious need to protect patients
from any harm, regulators need to recognize the
statistical uncertainties whereby effective treatments
might be unjustly removed on the basis of weak ev-
idence of potential harm arising from data dredging
across a multiplicity of endpoints.
COMPOSITE ENDPOINTS. These are commonly used
in CV RCTs to combine evidence across 2 or more
outcomes into a single primary endpoint. But, there is
a danger of oversimplifying the evidence by putting
too much emphasis on the composite, without
adequate inspection of the contribution from each
separate component. For instance, the SYNTAX
(Synergy between Percutaneous Coronary Interven-
tion with Taxus and Cardiac Surgery) trial (8,9)
of bypass surgery (CABG) versus the TAXUS
drug-eluting stent (DES) in 1,800 patients with left
main or triple-vessel disease had a major adverse
cardiac or cerebrovascular events (MACCE) composite
primary endpoint comprising death, stroke, MI, and
repeat revascularization; results at 1 and 5 years of
follow-up are shown in Table 2. At 1 year, there was
highly signiﬁcant excess of MACCE events after DES,
which, at face value, indicates that DES is inferior to
CABG. But here is a more complex picture not well
captured by this choice of primary endpoint. The
main difference is in repeat revascularization, of
which the great majority is repeat PCIs. One could
argue that 10% of patients having a second PCI is less
traumatic than the CABG received by 100% of the
CABG group, so this component of the primary
endpoint is not well representing the comparison ofoverall patient well-being. At 1 year, there is a sig-
niﬁcant excess of strokes after CABG, and no overall
difference in the composite of death, MI, and stroke.
A general principle that often occurs in other inter-
ventional trials (for example, complete or culprit
lesion intervention in primary PCI) is that clinically
driven interventions should not be part of the pri-
mary endpoint.
TABLE 3 Efﬁcacy Results From the EMPHASIS-HF Trial, With and
Without Covariate Adjustment
Adjusted HR
(95% CI)
p
Value
Unadjusted HR
(95% CI)
p
Value
Primary endpoint* 0.63 (0.54–0.74) <0.001 0.66 (0.56-0.78) <0.001
CV death 0.76 (0.61–0.94) 0.01 0.77 (0.62–0.96) 0.02
Hospitalization for heart failure 0.58 (0.47–0.70) <0.001 0.61 (0.50–0.75) <0.001
*Primary endpoint is the composite of CV death and hospitalization for heart failure. HRs and 95% CIs with and
without baseline covariate adjustment for efﬁcacy endpoints in the EMPHASIS-HF trial. Adjustment was made
using a proportional hazards model adjusting for 13 pre-deﬁned baseline covariates: age, estimated glomerular
ﬁltration rate, ejection fraction, body mass index, hemoglobin value, heart rate, systolic blood pressure, diabetes
mellitus, history of hypertension, previous MI, atrial ﬁbrillation, left bundle-branch block, or QRS duration
>130 ms. Data from Zannad et al. (12).
CV ¼ cardiovascular; EMPHASIS-HF ¼ Eplerenone in Mild Patients Hospitalization and Survival Study in Heart
Failure; other abbreviations as in Table 1.
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2652A second important point raised by SYNTAX is that
in such strategy trials, the key treatment differences
may well be revealed with longer-term follow-up. At 5
years, there is a highly signiﬁcant excess of MIs in the
DES group, and this drives the composite of death,
MI, and stroke also to be in favor of CABG.
This example illustrates how, for composite end-
points, “the devil lies in the details.” In the ongoing
EXCEL (Evaluation of XIENCE versus coronary artery
bypass surgery for effectiveness of left main revas-
cularization) (10) trial of CABG versus everolimus-
eluting stent in left main disease, the primary
endpoint is death, MI, and stroke after 3 years,
providing an appropriate longer-term perspective on
the key major CV events.
COVARIATE ADJUSTMENT. Should the key results of
an RCT be adjusted for baseline covariates, which
covariates should be chosen (and how), and which
results should be emphasized (11)? Practice varies
widely: for some RCTs only unadjusted results are
presented, others have covariate adjustment as their
primary analysis, and yet others use it as a secondary
sensitivity analysis. This inconsistency of approach
across trials is, perhaps, tolerated because in major
trials, randomization ensures good balance across
treatments for baseline variables, and hence, covari-
ate adjustment usually makes little difference.
The EMPHASIS-HF (Eplerenone in Mild Patients
Hospitalization and Survival Study in Heart Failure)
trial (12) of eplerenone versus placebo in 2,737
chronic heart failure patients illustrates the conse-
quences of covariate adjustment. The investigators
pre-deﬁned use of a proportional hazards model
adjusting for 13 baseline covariates: age, estimated
glomerular ﬁltration rate (GFR), ejection fraction,
body mass index, hemoglobin value, heart rate, sys-
tolic blood pressure, diabetes mellitus, history of
hypertension, previous MI, atrial ﬁbrillation, leftbundle-branch block, and QRS duration >130 ms.
Selection was sensibly on the basis of prior knowl-
edge/suspicion of each variable’s association with
patient prognosis. Table 3 shows the adjusted and
unadjusted HRs for eplerenone versus placebo for the
primary endpoint and also for its 2 separate compo-
nents. In all 3 instances, the adjusted HR was slightly
further from 1, as one would expect when adjusting
for factors that are related to prognosis (13). Unlike
normal regression models, covariate adjustment for
binary or time-to-event outcomes using logistic or
proportional hazard models does not increase the
precision of estimates (CI width changes little);
rather, point estimates, (e.g., odds ratio, HR) tend to
move further away from the null. Thus, there is a
slight gain in statistical power in adjusting for cova-
riates, but only if the chosen covariates are related to
patient prognosis. If, misguidedly, one chooses
covariates not linked to prognosis, then covariate
adjustment will make no difference.
One misperception is that covariate adjustment
should be done for the stratiﬁcation factors used in
randomization. This was speciﬁed in IMPROVE-IT
(Improved Reduction of Outcomes: Vytorin Efﬁcacy
International Trial) (14) in acute coronary syndrome,
where stratiﬁcation factors were prior lipid-lowering
therapy, type of acute coronary syndrome, and
enrollment in another trial (yes/no). Clearly, these are
not the most important issues affecting prognosis in
ACS (age is the strongest risk factor), and such
adjustment, although harmless, might be considered
of little value.
Adjustment for geographic region is also sometimes
performed. For example, PARADIGM-HF (Prospective
Comparison of ARNI [Angiotensin Receptor–Neprily-
sin Inhibitor] with ACEI [Angiotensin-Converting–
Enzyme Inhibitor] to Determine Impact on Global
Mortality and Morbidity in Heart Failure) (15)
adjusted HRs for 5 regions, 1 of which, curiously,
was Western Europe plus South Africa and Israel.
Again, this will do no harm, but is a cosmetic exercise,
missing out on the real purpose of covariate
adjustment.
Some argue that one should adjust for baseline
variables that show an imbalance between treatment
groups. For instance, the GISSI-HF (Gruppo Italiano
per lo Studio della Sopravvivenza nell’Insufﬁcienza
cardiaca-Heart Failure) trial (16) adjusted for vari-
ables that were unbalanced between randomized
groups at p < 0.1. As a secondary sensitivity analysis,
it can add reassurance that the primary analysis
makes sense. However, if the covariates with imbal-
ance again do not affect the prognosis, such adjust-
ment will make a negligible difference.
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2653Occasionally, when an unadjusted analysis ach-
ieves borderline signiﬁcance, the use of an appropri-
ately pre-deﬁned covariate adjustment can add
weight to the conclusions. For instance, in the
CHARM (Candesartan in Heart failure: Assessment of
Reduction in Mortality and morbidity) trial (17) in
7,599 heart failure patients, the unadjusted HR (can-
desartan vs. placebo) for all-cause death over a me-
dian 3.2 years was 0.90 (95% CI: 0.83 to 1.00;
p ¼ 0.055). A pre-speciﬁed secondary analysis, ad-
justing for covariates anticipated to affect prognosis,
gave an HR of 0.90 (95% CI: 0.82 to 0.99; p ¼ 0.032).
This added credibility to the idea of a survival beneﬁt
for candesartan, especially given that the covariate-
adjusted HR for CV death was 0.87 (95% CI: 0.78 to
0.96; p ¼ 0.006).
In general, we believe that a well-deﬁned appro-
priate covariate-adjusted analysis is well worth doing
in major RCTs. After all, it offers a slight gain in sta-
tistical power at no extra cost and with minimal sta-
tistical effort, so whymiss out on such an opportunity?
The following principles should be followed:
1. On the basis of prior knowledge, one should
specify clearly a limited number of covariates
known (or thought) to have a substantial bearing
on patient prognosis. Make sure such covariates
are accurately recorded at baseline on all patients.
2. Document, in a pre-speciﬁed SAP, the precise
covariate-adjusted model to be ﬁtted. For in-
stance, a quantitative covariate, such as age, can
be either ﬁtted as a linear covariate or in several
categories (age groups). Such a choice needs to be
made in advance.
3. Post-hoc variable selection (e.g., adding covariates
unbalanced at baseline, dropping nonsigniﬁcant
predictors, or adding in new signiﬁcant predictors
after database lock) should be avoided in the pri-
mary analysis because suspicions may arise that
such choices might have been made to enhance the
treatment effect.
4. Both unadjusted and covariate-adjusted analyses
should be presented, with pre-speciﬁcation as
to which is the primary analysis. If the choice
of covariates is conﬁdently supported by experi-
ence of what inﬂuences prognosis, then it makes
sense to have the covariate-adjusted analysis as
primary (18).
SUBGROUP ANALYSIS
Patients recruited in a major trial are not a homoge-
neous bunch: their medical history, demographics,
and other baseline features will vary. Hence, it is
legitimate to undertake subgroup analyses to seewhether the overall result of the trial appears to apply
to all eligible patients, or whether there is evidence
that real treatment effects depend on certain baseline
characteristics.
Of all multiplicity problems in reporting RCTs,
interpretation of subgroup analyses presents a
particular challenge (19). First, trials usually lack
power to reliably detect subgroup effects. Second,
there are many possible subgroups that could be
explored, and one needs to guard against data
dredging, eliciting false subgroup claims. Third, sta-
tistical signiﬁcance (or not) in a speciﬁc subgroup is
not a sound basis for making (or ruling out) any
subgroup claims; instead, one needs statistical tests
of interaction to directly infer whether the treatment
effect appears to differ across subgroups.
We explore these ideas in a few examples. First,
subgroup analyses for the PARADIGM-HF trial (15) are
shown in Figure 2. This kind of ﬁgure, called a Forest
plot, is the usual way of documenting the estimated
treatment effect within each subgroup (an HR in this
case) together with its 95% CI. The 18 subgroups
displayed were pre-speciﬁed and show a consistency
of treatment effect, all being in the direction of su-
periority for LCZ696 compared with enalapril in this
heterogeneous heart failure population for both the
primary endpoint and CV death. For reference, the
results for all patients, with their inevitably tighter
CIs, are shown at the top of Figure 2.
Scanning across subgroups, one can see that esti-
mated HRs vary by chance and CIs are wider for
smaller subgroups. Some CIs overlap the line of
unity, indicating that the subgroup p value does not
reach 5% signiﬁcance; this will inevitably happen,
especially in smaller subgroups, and is not helpful in
interpreting subgroup ﬁndings. Instead, a statistical
test of interaction should accompany each subgroup
display (as shown in Figure 2). This interaction test
examines the extent to which the observed differ-
ence in HRs across subgroups may be attributed to
chance variation. For the primary endpoint, just 1
interaction test is statistically signiﬁcant: p ¼ 0.03 for
New York Heart Association class I or II versus III or
IV, which suggests a possible greater beneﬁt of
LCZ696 in less symptomatic patients, although no
such interaction exists for CV death (interaction
p ¼ 0.76). Given that 18 subgroup analyses have been
performed for each of 2 outcomes, one could expect
at least 1 interaction p < 0.05 purely by chance, so
these data are overall supportive of a consistency of
treatment effect across a broad spectrum of patients
with heart failure.
When the overall result of a major RCT is neutral,
it is tempting to search across subgroups to see if
FIGURE 2 Pre-Speciﬁed Subgroup Analyses in the PARADIGM-HF Trial
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   ≤1 yr
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no.
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2044
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784
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953
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2646
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2299
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2116
2087
1218
2969
1241
2971
921
3266
946
3266
1916
2271
1812
2400
1580
2607
1545
2667
1275
1621
1291
1248
1611
1353
Hazard Ratio
(95% CI)
P value for
interaction
Hazard ratio
(95% CI)
P value for
interaction
0.47
0.32
0.63
0.58
0.37
0.03
0.91
0.40
0.87
0.71
0.36
0.25
0.16
0.87
0.09
0.10
0.10
0.27
0.70
0.62
0.92
0.88
0.81
0.76
0.73
0.05
0.62
0.80
0.36
1.00
0.33
0.14
0.06
0.32
0.19
0.21
Primary End Point Death from Cardiovascular Causes
Hazard ratios for the primary endpoint (death from cardiovascular causes or ﬁrst hospitalization for heart failure) and for death from car-
diovascular causes among patients in pre-speciﬁed subgroups. The size of the square corresponds to the number of patients in each subgroup.
Data from McMurray et al. (15). ACE ¼ angiotensin-converting enzyme; CI ¼ conﬁdence interval; GFR ¼ glomerular ﬁltration rate; NT-proBNP ¼
N-terminal pro-B-type natriuretic peptide; NYHA ¼ New York Heart Association; PARADIGM-HF ¼ Prospective Comparison of ARNI (Angio-
tensin Receptor–Neprilysin Inhibitor) with ACEI (Angiotensin-Converting–Enzyme Inhibitor) to Determine Impact on Global Mortality and
Morbidity in Heart Failure.
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2655there is a particular subgroup in which the treatment
effect is favorable. In this context, subgroup claims
require an especially cautious interpretation in a
journal publication. Furthermore, it is highly unlikely
that regulators, such as the Food and Drug Adminis-
tration (FDA), would approve a drug on the basis of
such a positive subgroup claim.
The CHARISMA (Clopidogrel For High Athero-
thrombotic Risk, Ischemic Stabilization, Manage-
ment, And Avoidance) trial (20) is an interesting case
in point. Against a background of low-dose aspirin,
15,603 patients at high risk of atherothrombotic
events were randomized to clopidogrel or placebo.
Over a median 28 months, incidence of the primary
endpoint (CV death, MI, or stroke) was 6.8% versus
7.3% (p ¼ 0.22). But, in symptomatic patients (78% of
all patients), the ﬁndings for clopidogrel looked bet-
ter: 6.9% versus 7.9% (p ¼ 0.046). In contrast, the
results trended in the opposition direction in
asymptomatic patients: 6.6% versus 5.5% (p ¼ 0.02).
The interaction test had p ¼ 0.045, and the authors’
conclusions included a claim of beneﬁt for clopidog-
rel in symptomatic patients.
The accompanying editorial was critical, com-
menting that “the charisma of extracting favorable
subgroups should be resisted” (21). Why? Well, this
was 1 of 12 pre-speciﬁed subgroup analyses, and the
strength of evidence, p for interaction, was border-
line. Also, it is usually biologically implausible that a
true treatment effect will be in opposite directions
across subgroups; that is, so-called qualitative in-
teractions rarely arise across clinical medicine. The
New England Journal of Medicine has subsequently
toughened its policy regarding subgroup analyses
(22), so that they are seen more as exploratory and
hypothesis-generating, rather than as part of a trial’s
key conclusions.
A different challenge arises when the overall
results of a trial are positive, but there appears to
be a lack of superiority in a particular subgroup.
For instance, the SPIRIT (Clinical Evaluation of
the XIENCE V Everolimus Eluting Coronary Stent
System) IV (23) trial comparing everolimus-eluting
stents (EES) or paclitaxel-eluting stents in 3,687
patients showed overall superiority for EES for the
primary endpoint, target lesion failure at 1 year:
4.2% versus 6.8% (p ¼ 0.001). But, in 1,140 diabetic
patients (1 of 12 subgroup analyses), there was no
evidence of a treatment difference: 6.4% versus 6.9%
(interaction p ¼ 0.02). This ﬁnding in itself is not
deﬁnitive evidence, and hence, further evidence
was sought to conﬁrm (or refute) this ﬁnding. A
pooled analysis of 2-year outcomes across 4 RCTs of
EES versus paclitaxel-eluting stents in 6,780 patients(24) revealed marked superiority of EES in nondia-
betic subjects for death, MI, stent thrombosis,
and ischemia-driven target lesion revascularization,
whereas no such beneﬁts of EES existed for diabetic
patients. All 4 interaction tests were convincingly
signiﬁcant: p ¼ 0.02, p ¼ 0.01, p ¼ 0.0006, and
p ¼ 0.02, respectively.
Although such conﬁrmatory evidence of an initial
subgroup ﬁnding is highly desirable, it is not always
achievable. But, regulatory decisions still need to be
made on whether apparent lack of efﬁcacy in a sub-
group merits a speciﬁc restriction with regard to drug
approval. For instance, the European Medicines
Agency restricted use of ivabradine in chronic heart
failure to patients with heart rate$75 beats/min on the
basis of a signiﬁcant interaction in 1 pivotal trial (25).
Overall, there is a responsibility to perform and
present subgroup ﬁndings from major RCTs. Pre-
speciﬁcation of a limited number of intended sub-
group analyses is a helpful guard against post-hoc
manipulations of data, but interpretations are still
restricted by a lack of statistical power and a multi-
plicity of hypotheses, so due caution is required to
not overreact to any subgroup claims. Subgroup
analysis becomes most convincing when it relates to
just 1 pre-declared factor of especial interest (e.g.,
troponin-positive vs. negative in GP IIb/IIIa trials),
where an interaction is anticipated to exist.
ASSESSING INDIVIDUAL BENEFITS
AND RISKS
In most RCT reports, the focus is on the overall rela-
tive efﬁcacy and relative safety of the treatments
being compared. But even in the absence of any
subgroup differences on a relative scale (e.g., on the
basis of HRs or odds ratios), there may well be
important differences between individuals as regards
absolute treatment beneﬁts (26).
For instance, in the EMPHASIS-HF trial (12) of
eplerenone versus placebo in heart failure, patients
with mild symptoms, the composite primary
endpoint, CV death, and heart failure hospitalization,
showed a marked beneﬁt over a median 21-month
follow-up (HR: 0.63; 95% CI: 0.54 to 0.74;
p < 0.0001). There were no apparent subgroup effects
on a hazard ratio scale. In a subsequent analysis, each
patient was then classiﬁed into low-, medium-, and
high-risk groups on the basis of a multivariable risk
score using 10 commonly-recognized prognostic fea-
tures (27). Table 4 shows the consequent treatment
beneﬁts by risk group, on both relative and absolute
scales. As anticipated, the HR was similar in all risk
groups. But, the absolute beneﬁts varied markedly by
TABLE 4 Primary Endpoint Event Rates by Risk Group and Treatment in the EMPHASIS-HF Trial
Risk Group
Treatment
Group
Number of
Patients
Number of
Events Rate* HR (95% CI) Rate Difference (95% CI)
Low Placebo 643 103 7.61 0.74 (0.56, 0.99) 1.98 (3.89 to 0.06)
Eplerenone 648 81 5.63
Mid Placebo 478 164 19.00 0.64 (0.50, 0.82) 6.80 (10.54 to 3.06)
Eplerenone 445 104 12.20
High Placebo 252 125 39.42 0.63 (0.49, 0.82) 15.22 (23.57 to 6.88)
Eplerenone 271 103 24.19
*Rate per 100 person-years; primary endpoint is the composite of CV death and heart failure hospitalization. Event rates, HRs, and rate differences for the primary endpoint
(CV death and hospitalization for heart failure) by risk group in the EMPHASIS-HF trial. Data from Collier et al. (27).
Abbreviations as in Tables 1 and 3.
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primary event rate per 100 patient-years was 2.0, 6.8,
and 15.2 in low-, medium- and high-risk patients,
respectively. Inevitably, when there is no interaction
on a relative scale, there will often be a marked
interaction on an absolute scale across subgroups of
differing risk status.
Pooling of data for 3 trials (28) of routine invasive
versus selective invasive strategies in acute coronary
syndrome found a signiﬁcant difference in the 5-year
risk of CV death or MI (HR: 0.81; 95% CI: 0.71 to 0.93;
p ¼ 0.002). This was consistent across risk groups,
but, when expressed on an absolute scale, the beneﬁt
of a routine invasive strategy is more marked in
higher-risk patients: for low-, intermediate-, and
high-risk patients, the reductions in 5-year risk of CV
death and MI were 2.0%, 3.8%, or 11.1%, respectively.
In contrast, it could happen that higher-risk patients
have a lower relative beneﬁt, but because of their
higher risk, their absolute beneﬁt was similar to those
at lower risk (e.g., the elderly [age >75 years] and
ﬁbrinolysis).
These 2 examples illustrate how one needs to
consider the individual’s risk status in determining
whether the absolute beneﬁt of an intervention is
sufﬁcient to merit its use in each case. Note that this
is achieved by multivariable risk analysis, rather than
univariate subgroups. This becomes particularly
important if treatment efﬁcacy is offset by a risk of
side effects. For instance, TRITON-TIMI 38 (Trial to
Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with Prasugrel—
Thrombolysis In Myocardial Infarction 38) (29)
compared prasugrel with clopidogrel in 13,608 pa-
tients with acute coronary syndrome. Over a median
14.5 months, incidence of the primary endpoint (CV
death, MI, and stroke) was less on prasugrel (9.9% vs.
12.1%; HR: 0.81; 95% CI: 0.73 to 0.90; p < 0.001). This
beneﬁt was mainly due to a reduction in nonfatal
MIs: 7.3% versus 9.5%. However, there were morebleeding events on prasugrel; for example, TIMI
(Thrombolysis In Myocardial Infarction) major bleed
(2.4% vs. 1.8%; p ¼ 0.03).
To weigh the beneﬁts and risks of prasugrel versus
clopidogrel on an individual patient basis, Salisbury
et al. (30) used multivariable logistic models to
separately predict any patient’s risk of: 1) the primary
ischemic endpoint; and 2) TIMI major or minor bleed,
taking account of both randomized treatment and
patient characteristics. The intent is to quantify, on
an absolute scale, how the tradeoff between treat-
ment differences in ischemic efﬁcacy and bleeding
harm is patient-speciﬁc. For instance, the bleeding
risk is of greater concern in elderly women, whereas
in a younger man with known CV risk factors,
avoidance of future ischemic events is paramount.
Clopidogrel is the drug of choice for the former,
whereas prasugrel is a better choice for the latter.
These multivariable models are a quantitative aid to
such clinical judgment, and may be of particular use
in the broader spectrum of patients for whom the
efﬁcacy/safety tradeoff is less clinically obvious.
Similar principles can apply when deciding what
dose of a drug is appropriate for the individual patient.
In stroke prevention for patients with atrial ﬁbrilla-
tion, the RE-LY (Randomized Evaluation of Long-
Term Anticoagulation Therapy) (31) and ENGAGE AF-
TIMI 48 (Effective Anticoagulation with Factor Xa
Next Generation in Atrial Fibrillation—Thrombolysis
In Myocardial Infarction 48) (32) trials are to be com-
mended for comparing 2 different anticoagulant drug
doses (of dabigatran and edoxaban, respectively)
against warfarin. In both 3-arm trials, the higher dose
appeared to be more effective in reducing the risk of
stroke and systemic embolism, whereas the lower
dose had fewer bleeding events. At present, these 2
trials have conﬁned attention to the overall ﬁndings
and conventional subgroup analyses, whereas we
would encourage more model-based approaches to
better identify which types of patients (if any) would
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2657have a net beneﬁt from the lower dose. Ideally, such
risk models should be on the basis of external data,
but, realistically, this is often not possible.
In general, reports of clinical trials mainly focus on
an overall treatment comparison, with cautious
reference to subgroup analyses of 1 baseline variable
at a time. Therefore, the opportunity to link trial
ﬁndings to individualized patient care on the basis
of “whole patient” risk proﬁles is largely being
missed (33).
ANALYSIS BY ITT AND OTHER OPTIONS
Analysis by ITT means that a trial’s results include the
totality of patient follow-up for all randomized pa-
tients. For major RCTs with a superiority hypothesis,
it is generally regarded as the main approach to
reporting of trial ﬁndings for treatment efﬁcacy in
both medical journals and regulatory submissions.
The advantage of ITT is that it provides an unbiased
comparison of treatment strategies as delivered in
practice: there is no scope for post-hoc selection of
who to include or for how long. Everyone is included,
with no escape! Such logic appears soundly based, but
there are 2 complications to consider: 1) do we truly
have full follow-up data available for everyone; and 2)
are we really happy to include all protocol deviations
in a pure ITT, or is a modiﬁed ITT appropriate?
On the ﬁrst point, the more patients that are
lost to follow-up, the further the attempted analysis
deviates from true ITT. In trial conduct, it is impor-
tant to minimize loss to follow-up. High treatment
compliance is a ﬁrst step. Also, when patients do
withdraw from treatment, their follow-up should
continue, if at all possible. In most time-to-event
analyses, there is variation in observed patient
follow-up: commonly, recruitment takes 1 to 2 years,
and all patients are followed to a ﬁxed calendar date.
If all patients not experiencing a primary endpoint
reach that date, then a true ITT analysis is done, and
in producing Kaplan-Meier plots (among others)
censoring is sensibly assumed to be noninformative.
But, if patients are lost to follow-up at an earlier
stage, this cannot be assumed to occur at random. For
example, patients who drop out may be sicker and
hence at higher risk of a primary event, which goes
unrecorded. Thus, loss to follow-up is potentially
informative censoring and could lead to a biased
treatment comparison. This becomes particularly
serious if the dropout rates, and their reasons, differ
between treatment groups.
The ATLAS ACS 2 (Anti-Xa Therapy to Lower Car-
diovascular Events in Addition to Standard Therapy in
Subjects With Acute Coronary Syndrome ACS 2) trial(34) illustrates this problem. This 3-arm trial compared
2 doses of rivaroxaban and placebo in 15,526 patients
followed for a mean of 13 months. Published ﬁndings
looked particularly good for the lower rivaroxaban
dose, with superiority for the primary endpoint (CV
death, MI, and stroke) and for all-cause death,
although with some increase in bleeding events
compared with placebo. However, under the scrutiny
of an FDA Advisory Panel, the extent of incomplete
follow-up became evident, with 15.5% of patients
prematurely discontinued from the study. Speciﬁcally,
8.3% withdrew consent, for whom the great majority
had unknown vital status at the trial’s end. This prob-
lem cast sufﬁcient doubt on the robustness of the trial
ﬁndings to inﬂuence the FDA panel not to recommend
approval. There is no ﬁxed guidance as to what level of
dropout becomes unacceptable. ATLAS ACS 2 clearly
did less well in this regard than several other recent
trials in acute coronary syndrome, although, of course,
none could achieve 100% follow-up (35).
Although presenting ITT analyses, ATLAS ACS 2
(33) put greater emphasis on what they called a
modiﬁed ITT approach; that is, any events occurring
more than 30 days after study drug discontinuation
were excluded from analysis. This is perhaps more
commonly called a “per-protocol” or “on-treatment”
analysis, and is usually downgraded to a secondary
analysis with the prime focus on ITT. Use of the term
“modiﬁed ITT” is quite common in clinical trial re-
ports, but there is a lack of consistency in what it
means. Less desirable features are any post-
randomization exclusions, because these could lead
to bias (36). More acceptable modiﬁcations are ex-
clusions of ineligible patients incorrectly randomized
and, in double-blind trials, exclusions of any patients
who never got a single dose of the study drug.
The APPROVe (Adenomatous Polyp Prevention on
Vioxx) trial (37,38) illustrates how obtaining an
appropriate ITT analysis is important in reaching
valid conclusions. The trial found an excess risk of CV
events on rofecoxib compared with placebo in 2,586
patients with a history of colorectal adenomas. The
ﬁrst report only included events occurring during
treatment and up to 14 days after the last dose: 46
patients versus 26 patients with thrombotic events
(p ¼ 0.008). It was claimed that event rates were
similar in the ﬁrst 18 months, and the excess only
emerged thereafter (Figure 3A). This “on-treatment”
analysis did not give the whole story, and a subse-
quent ITT analysis, still with some missing follow-up,
revealed a somewhat different pattern. There were
now 59 patients versus 34 patients with thrombotic
events (p ¼ 0.006), and the evidence appeared
compatible with an early increase in risk that persists
FIGURE 3 Excess Risk of Thrombotic Events on Rofecoxib in the APPROVe Trial,
First as On-Treatment Analysis and Subsequently as ITT Analysis
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Kaplan-Meier cumulative frequency of thrombotic events in the APPROVe trial calculated
from an (A) on-treatment analysis and (B) ITT analysis. Data from Bresalier et al. (37) and
Baron et al. (38). APPROVe ¼ Adenomatous Polyp Prevention on Vioxx; APTC ¼ Anti-
platelet Trialists’ Collaboration; ITT ¼ intention-to-treat.
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26581 year after stopping treatment (Figure 3B). Rofecoxib
was withdrawn from worldwide markets due to these
safety concerns, although it is worth noting that the
second report (38) was published over 3 years after
this withdrawal.
For a trial in which both noninferiority and superi-
ority hypotheses are of interest, both per-protocol
analysis and ITT analysis are relevant. For non-
inferiority testing, the per-protocol analysis is often
deemed primary, on the basis that ITT includes time
when patients are off the study drug, whichmay diluteany real treatment effects, making it artiﬁcially too
easy to claim noninferiority. But for tests of superi-
ority, ITT gets priority. The TECOS trial (7) of sita-
gliptin versus placebo in type 2 diabetes illustrates this
approach. The primary event (CV death, MI, stroke,
unstable angina) occurred in 839 patients versus 851
patients in ITT analysis (p ¼ 0.65). Over a median
3 years of follow-up, a sizeable minority of patients
stopped taking their study drug. Thus, per-protocol
analysis had 695 primary events versus 695 primary
events (HR: 0.98; 95% CI: 0.88 to 1.09). Noninferiority
of sitagliptin was clearly established, and there is no
evidence that it reduces risk of CV events. In both
treatment groups, the event rates in ITT analysis are
higher than in per-protocol analysis. That is, becoming
nonadherent is associated with a higher risk, which is
a common feature across most RCTs.
ROCKET-AF (Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation) (39), which compared riv-
oraxaban and warfarin in 14,264 patients with atrial
ﬁbrillation, had a similar construct, with both non-
inferiority and superiority hypotheses. In ITT analysis,
the primary event, stroke or systematic embolism,
occurred less frequently on rivaroxaban: 269 events
versus 306 events (HR: 0.88; 95% CI: 0.75 to 1.03;
p ¼ 0.12). Given this lack of signiﬁcance, interest
turned to the events occurring on study drug (plus
within 2 days of stopping), the per-protocol popula-
tion: 188 events versus 240 events (HR: 0.79; 95% CI:
0.66 to 0.96; p ¼ 0.02). However, this secondary
analysis for superiority, with its potential bias, as al-
ways, did not sway the evidence toward a claim of
superiority and the published conclusion was “rivar-
oxaban was noninferior to warfarin for the preven-
tion of stroke or systemic embolism.” In general,
per-protocol analyses introduce bias: nonadherent
patients are a select group, often (but not automati-
cally) at high risk of outcome events, which makes
interpretation unreliable.
In unblinded trials of alternative treatment strate-
gies, there is a risk that some patients do not pursue
their randomly allocated strategy. For instance, in the
PARTNER (Placement of Aortic Transcatheter Valves)
trial (40) of transcatheter aortic valve replacement
versus aortic valve surgery, there were 4 (1%) and 38
(11%) patients, respectively, who did not get their
intended treatments. ITT from randomization was the
primary analysis. However, a supplementary as-
treated analysis from time of treatment (excluding
those 42 patients) helped to conﬁrm that there was no
mortality difference, but a borderline signiﬁcant
excess of strokes. In this situation, ITT will tend to
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a valid comparison of strategies along with their pro-
tocol deviations), and an as-treated analysis may be
biased. For example, it may be higher-risk patients
who declined surgery. A consistency across the 2 anal-
yses is helpful. For noninferiority trials, both ITT
and per-protocol analyses should be presented, a point
we will clarify further in the last paper of this series.
INTERPRETING SURPRISES,
BOTH GOOD AND BAD
From time to time, an unexpected ﬁnding arises from
a clinical trial. The surprise may relate to an endpoint
for which there was no prior hypothesis, a subgroup
that appears inconsistent with the overall treatment
effect, or an unduly large treatment effect that ex-
ceeds prior expectations. It may relate to treatment
beneﬁt or harm.
The cycle of progress in medical research needs to
be borne in mind. A new dramatic claim (whether
beneﬁt or harm) is often on the basis of a small study.
Accordingly, it is prone to exaggerate the issue, even
if the study has no design ﬂaw. The issue becomes
high proﬁle without adequate recognition of all of the
selection biases that have occurred, for example,
across multiple analyses (endpoints, trials, and sub-
groups). If one focuses on the most extreme result, it
will look more impressive than is justiﬁed.
One then needs to collect more substantial evi-
dence on the issue, for example, continued follow-up,
a larger trial, or a meta-analysis of related trials. Some
“regression to the truth” is liable to occur whereby
the consequent effect turns out to be more modest
and, sometimes, not present at all. We illustrate this
pattern with some examples, starting with potential
safety concerns arising from RCTs.
In the SEAS (Simvastatin and Ezetimibe in Aortic
Stenosis) trial (41) in 1,873 patients with aortic steno-
sis, the active treatment, simvastatin plus ezetimibe,
had an unexpected excess of cancers compared with
placebo: 105 incident cancers versus 70 incident can-
cers (p ¼ 0.01), and 39 cancer deaths versus 23 cancer
deaths (p ¼ 0.05). Given the wealth of safety data
available on statins, the potential culprit was thought
to be ezetimibe. There was an urgent need to study the
totality of evidence regarding ezetimibe and cancer.
Hence, 2 ongoing, large trials of ezetimibe versus pla-
cebo on background statins, SHARP (Study of Heart
and Renal Protection) and IMPROVE-IT, published
their combined interim ﬁndings: 313 incident cancers
versus 329 incident cancers (p ¼ 0.61) and 97 cancer
deaths versus 72 cancer deaths (p ¼ 0.07) for the eze-
timibe and placebo groups, respectively (42). Therewas also no logical pattern with respect to speciﬁc
cancers. The conclusion was that “the available evi-
dence do not provide any credible evidence of any
adverse effect of ezetimibe on rates of cancer,” which
was conﬁrmed by the larger numbers of events in the
ﬁnal results of these 2 trials.
A similar pattern emerged with an apparent
excess of MIs on rosiglitazone, ﬁrst proposed in a
meta-analysis by Nissen and Wolski (43) (odds ratio
vs. control: 1.43; 95% CI: 1.03 to 1.98; p ¼ 0.03). The
main subsequent evidence came from the RECORD
(Rosiglitazone Evaluated for Cardiovascular Out-
comes in Oral Agent Combination Therapy for Type 2
Diabetes) trial (44) in 4,447 diabetic patients followed
for a mean of 5.5 years: the HR for MI (rosiglitazone vs.
active control) was 1.14 (95% CI: 0.80 to 1.63; p ¼ 0.47).
After much FDA scrutiny over several years, it was
ﬁnally concluded that rosiglitazone does not increase
the risk of MI. However, the overall safety proﬁle,
especially risks of heart failure and bone fractures,
meant that the marketing authorization for the drug
was suspended in Europe. One general lesson here is
that meta-analyses of small trials require a very
cautious interpretation, pending more solid evidence
from large prospective randomized trials.
Another possibility is that a drug’s initial signal of
harm is exaggerated, but further evidence does sub-
stantiate that a real problem exists. For instance, the
ﬁrst evidence of risk of MI attributed to rofecoxib
came from the VIGOR (Vioxx Gastrointestinal Out-
comes Research) trial (45) of rofecoxib versus nap-
roxen in patients with rheumatoid arthritis: 20 MIs
versus 4 MIs, relative risk 5.00 (95% CI: 1.68 to 20.13).
Curiously, the original publication reported it as a
beneﬁt of naproxen, with relative risk 0.2 (95% CI: 0.1
to 0.7). Here, it is important to note the small
numbers of events and, hence, the wide CI. Subse-
quent evidence, both from the APPROVe trial (37) (see
previous text) and from meta-analyses, showed an
effect closer to a doubling of risk, rather than a 5-fold
increase. Furthermore, the meta-analysis showed no
heterogeneity of this risk across the class of Cox-2
inhibitors (46). So, was rofecoxib “the unlucky one”
to ﬁrst focus attention on this class phenomenon?
We now turn to claims of treatment efﬁcacy on the
basis of apparently large beneﬁts in small trials. For
instance, a trial of acetylcysteine versus placebo (47) for
prevention of contrast-induced nephropathy in 83 pa-
tients revealed 1 acute reduction versus 9 acute redu-
ctions in renal function (p¼0.01). This topic has yielded
a number of other small trials, andmeta-analyses of the
collective evidence show that ﬁndings are too incon-
sistent to warrant a conclusion of efﬁcacy. A large,
well-designed trial is needed to resolve this issue.
TABLE 5 CONSORT Checklist of Items to Include When Reporting a Randomized Trial
Section/Topic
Item
Number Checklist Item
Title and abstract
1a Identiﬁcation as a randomized trial in the title
1b Structured summary of trial design, methods, results, and conclusions (for speciﬁc guidance, see CONSORT for abstracts)
Introduction
Background and objectives 2a Scientiﬁc background and explanation of rationale
2b Speciﬁc objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial), including allocation ratio
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group, with sufﬁcient details to allow replication, including how and when they were actually
administered
Outcomes 6a Completely deﬁned pre-speciﬁed primary and secondary outcome measures, including how and when they were assessed
6b Any changes to trial outcomes after the trial commenced, with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and stopping guidelines
Randomization
Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomization; details of any restriction (such as blocking and block size)
Allocation concealment
mechanism
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any
steps taken to conceal the sequence until interventions were assigned
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions
Blinding 11a If done, who was blinded after assignment to interventions (e.g., participants, care providers, those assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
Participant ﬂow (a diagram is
strongly recommended)
13a For each group, the number of participants who were randomly assigned, received intended treatment, and were analyzed for
the primary outcome
13b For each group, losses and exclusions after randomization, together with reasons
Recruitment 14a Dates deﬁning the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group
Numbers analyzed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original
assigned groups
Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as
95% conﬁdence interval)
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-
speciﬁed from exploratory
Harms 19 All important harms or unintended effects in each group (for speciﬁc guidance see CONSORT for harms)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
Generalizability 21 Generalizability (external validity, applicability) of the trial ﬁndings
Interpretation 22 Interpretation consistent with results, balancing beneﬁts and harms, and considering other relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders
Data from Moher et al. (51).
CONSORT ¼ Consolidated Standards of Reporting Trials.
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2660There is an ongoing controversy concerning the
perioperative use of beta-blockers in noncardiac
surgery. The small DECREASE (Dutch Echocardio-
graphic Cardiac Risk Evaluation Applying StressEchocardiography) trial (48) of bisoprolol showed
apparently marked beneﬁts: in 112 patients there
were 2 deaths versus 9 deaths (p ¼ 0.02) and 0 MIs
versus 9 MIs (p < 0.001) in the bisoprolol and control
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2661groups, respectively. In general, it is wise to consider
such dramatic ﬁndings on the basis of small numbers
as being too good to be true. Sadly, in this case, sci-
entiﬁc misconduct became evident, making the study
untrustworthy, and current guidelines indicate that
the collective valid evidence concerning the value of
beta-blockers is inconclusive. Again, a large, well-
designed trial is needed.
The PRAMI (Preventive Angioplasty in Acute
Myocardial Infarction) trial (49) of preventive angio-
plasty versus stenting of the culprit lesion only is an
example of an apparently very large treatment effect
on the basis of relatively small numbers of events: 53
primary endpoints versus 21 primary endpoints (re-
fractory angina, MI, or cardiac death; HR: 0.35; 95%
CI: 0.21 to 0.58; p < 0.001). For any intervention to
reduce an event rate by more than one-half strikes
one as implausible. Here, the trial stopped early:
recruitment had been slow (and hence perhaps not
representative), and the trial was unblinded; all of
these may have contributed to an exaggeration of
effect. Findings from a larger sequel trial, COMPLETE
(Complete vs Culprit-only Revascularization to Treat
Multi-vessel Disease After Primary PCI for STEMI)
(50), are awaited with interest.
ENHANCING THE QUALITY OF
CLINICAL TRIAL REPORTS
We conclude with some general remarks about the
overall quality of clinical trial publications. CONSORT
(Consolidated Standards of Reporting Trials) (51) is an
established set of guidelines for reporting clinical
trials to which many journals, including JACC, expect
authors to adhere. There is a helpful checklist ofitems to include (Table 5) that covers all sections of
a paper, including the methods, results, and con-
clusions. Speciﬁc issues covered in CONSORT exten-
sions include noninferiority trials, pragmatic trials,
reporting of harms, and what to include in a trial
abstract (52).
Such guidelines do help, but the overall re-
sponsibility of trialists (and journal editors and re-
viewers) is to ensure that an honest, balanced
account of a trial’s ﬁndings is provided. In particular,
the discussion should document any limitations in
a trial’s design (e.g., what potential biases exist),
conduct (e.g., noncompliance, dropouts) and analysis
(e.g., was ITT analysis achieved). Relevant to the
controversies discussed in this paper is that authors
should make the pre-deﬁned analyses and any pri-
orities among them clear: for example, the primary
endpoint’s overall analysis should dominate the
conclusions and the abstract, whereas any important
safety issues should also be adequately represented
in both. Any other data explorations, (e.g., secondary
endpoints, subgroup analyses) are relevant back-
ground, but it is the authors’ and journal’s
responsibility to ensure that a cautious interpreta-
tion is maintained. Nevertheless, controversies will
continue to arise, and we hope this paper has pro-
vided a statistical insight that will help trialists
to present and readers to acquire a balanced
perspective.
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